Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology - Top-Institutions - MDSpire

Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

  • By

  • June 23, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology

  • #2

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Hematology

  • #3

    Thomas Jefferson University
    Thomas Jefferson University

    Philadelphia, PA

    Key Differentiators

    • Hematology

  • #4

    University of Chicago
    University of Chicago

    Chicago, IL

    Key Differentiators

    • Hematology

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology

Original Source(s)

Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

  • by

  • June 23, 2026

Related Content

Surgical Manual from Roswell Park Created to Advance Bladder Cancer Surgery Worldwide

Roswell Park Comprehensive Cancer Center announces the release of a new operative surgical manual authored by Khurshid Guru, MD.

  • by

  • July 8, 2026

  • 5 min
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

  • June 25, 2026

  • 1 min